We believe that the reduction of TF antibodies in cancer patients may represent in part a secondary phenomenon and be due to the expression of TF in the tumor or the appearance of TF-positive glycoconjugates (MUC1, etc.)in the circulation and elimination of TF antibodies via formation of immune complexes. Here, MUC1 is linked to cancer.